All Controlled release and advanced delivery articles – Page 6
-
ArticleATRAG formulations for lung disease
Carl-Johan Dalsgaard, CEO of Vicore Pharma speaks to EPR about clinical trials of C21, an angiotensin II type 2 receptor agonist developed to treat rare lung diseases – and the first ever ATRAG to reach clinical-stage development.
-
NewsNext-gen sustainable inhalers on the horizon
Global development and manufacture of the next generation of green inhalers is positioned to be accelerated by a new joint £33 million government-industry investment.
-
NewsTen-minute subcutaneous injection shows promise for MS
A Phase III trial for the only therapy approved for both relapsing and primary progressive multiple sclerosis (MS) met its clinical endpoints, Genentech has announced.
-
VideoWebinar: A rational approach to excipient selection for solid dose formulation and development
When developing a formulation for an immediate-release tablet, critical attributes of the active ingredient, including concentration, compactability, flowability, and solubility typically guide excipient selection.
-
NewsNew approach for small molecule nanosimilar analysis reported
A study on the small molecule antibiotic rifabutin has highlighted benefits of mechanistic compartmental analysis in evaluating nanomedicines.
-
NewsCould novel robotic oral pill replace traditional injections?
An osteoporosis study has demonstrated a high delivery success rate for a breakthrough technology that converts injections into an oral pill, data from ENDO 2023 showed.
-
NewsWhy is microbiological testing in medical device manufacturing important?
Careful planning during manufacture means accurate microbiology testing methods can be developed, ensuring the safety and efficacy of medical devices, a paper reports.
-
VideoVideo: High adhesion coating tablet with VIVACOAT® A
VIVACOAT® A shows outstanding adhesion to tablet cores achieved by using globally accepted excipients. Low adhesion can be the reason for the frequently observed effect of "logo bridging“.
-
NewsNew UK drug delivery centre to support RNA therapeutic development
To develop new lipid nanoparticle formulations for RNA therapeutic delivery technologies, CPI and partners are working to establish a new UK Intracellular Drug Delivery Centre.
-
NewsNICE recommends oral migraine treatment for first time
An oral small molecule CGRP antagonist has been recommended for episodic migraines in National Institute for Health and Care Excellence (NICE) final draft guidance.
-
Whitepaper
Whitepaper: Lipid-based nanoparticles: Manufacturing and inline size characterisation
Lipid-based Nano Particles form a very useful class of delivery systems in the pharmaceutical area as well as in cosmetics (and food/nutraceuticals).
-
Webinar
Route scouting for a cost-effective process development
Watch this webinar to discover how route scouting and polymorph screening at early stages of clinical trials can support scale up to commercial manufacturing.
-
Event2023 PDA Universe of Pre-Filled Syringes and Injection Devices Conference
The 20th conference edition is the perfect platform to present breakthrough innovations, and contribute to the pharmaceutical and medical device industries.
-
NewsPharmapack Awards 2024 entries open
Entries are open for the Pharmapack Awards 2024, which aims to showcase innovations in global drug delivery and packaging.
-
VideoVideo: Optimise continuous manufacturing using PROSOLV® EASYtab
In a continuous process, mono-functional excipients must be added through individual feeders, possibly resulting in multiple sources of variability.
-
WhitepaperPress release: SGS launches SGS PACE, a streamlined pathway through preclinical, formulation, FIH and POC
SGS PACE is a seamless combination of world-leading development, bioanalysis and clinical research through one point of contact.
-
NewsIntratumoural viral delivery improves glioblastoma survival
“Injecting a virus into a patient’s brain tumour” combined with immunotherapy improved glioblastoma survival outcomes in a clinical trial.
-
NewsCould personalised mRNA vaccine be first for cancer?
Half of pancreatic ductal adenocarcinoma (PDAC) patients given a personalised mRNA neoantigen vaccine experienced delayed recurrence 18 months post-vaccination.
-
NewsNovel device opens blood-brain barrier to deliver chemotherapy
A novel ultrasound technique opened the blood-brain barrier to successfully deliver chemotherapy to glioblastoma patients in a first-in-human trial.
-
ArticleRealising the potential of AAV gene therapies
In this article, Dr Rajiv Vaidya, Head of Manufacturing Science & Technology at Andelyn Biosciences, explores strategies for improving the scalability and cost‑effectiveness of AAV production while maintaining regulatory compliance.